APELLIS PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: A. Sinclair Dunlop

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: A. Sinclair Dunlop”): 54,091,088 for, 26,037,795 withheld, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 68% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 28,665,899 for, 4,059,757 withheld, 4 abstained, 740 not voted.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: Alec Machiels

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Alec Machiels”): 62,314,110 for, 17,814,774 withheld, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 29,574,063 for, 3,151,594 withheld, 2 abstained, 740 not voted.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: Keli Walbert

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Keli Walbert”): 76,951,740 for, 3,177,144 withheld, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 32,517,454 for, 208,205 withheld, 1 abstained, 740 not voted.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: To hold an advisory vote to approve the compensation paid to our named executive officers;

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers.”): 75,901,920 for, 4,167,103 against — passed, per its Form 8-K filed June 4, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(c) The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 59 managers: 32,230,743 for, 494,181 against, 735 abstained, 740 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 209 managers: 57,306,735 for, 3,500,464 against, 36,338 abstained, 9,627 not voted, 53,975 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To hold an advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers; and

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 58 managers: 735 abstained, 740 not voted, 32,720,213 1 year, 1,571 3 year, 1 unknown, 0 2 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 200 managers: 96,909 for, 2,549 against, 9,627 not voted, 48,370,381 1 year, 142,947 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 103,876,326 for, 54,603 against — passed, per its Form 8-K filed June 4, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(b) The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 32,723,901 for, 1,023 against, 735 abstained, 740 not voted.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.